Keywords: GlaxoSmithKline, Nabi, Smoking cessation, Vaccine, Licensing
GSK and Nabi in deal for NicVAX, with upfront and potential payments of over $500 million
Article | 17 November 2009
GlaxoSmithKline Biologicals SA, a unit of UK drugs giant GlaxoSmithKline, has entered an exclusive worldwide option and licensing agreement for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
